- IVAbciximabReoproLong half-life (8-12 hours) and effect (haemostasis 72 hours)
- Mechanism of Action
- Inhibits glycoprotein IIb/IIIa receptors, preventing them from binding to plasma adhesive proteins such as fibrinogen and von Willebrand factor (vWF) and facilitating platelet adhesion.
- Prevention of cardiac ischaemia post percutaneous coronary intervention (with aspirin + heparin)
- Adverse Effects